Arkolith/Insider Trading/RPHM/Form 4

Cruse Michael

Chief Operating OfficerReneo Pharmaceuticals, Inc. (RPHM) · full profile →Form 4 · filed Dec 13, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 9, 2022Grant(A)125K—$0125K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-061031) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML